GLYCOSYLTRANSFERASE LUMINESCENCE ASSAY: A NEW TECHNOLOGY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1989
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
11250
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Ela Technologies Inc
Box 6033, Athens, GA, 30604
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
ALTERATIONS IN GLYCOSYLTRANSFERASE ACTIVITIES HAVE BEEN CORRELATED WITH CERTAIN PATHOLOGICAL CONDITIONS AND DISEASESIN ANIMALS. THE CURRENT TECHNOLOGY FOR ASSAYING THESE ENZYMES IS NOT READILY ADAPTABLE FOR LARGE-SCALE CLINICAL SCREENING AND DIAGNOSTICS. IN THESE STUDIES, A NEW AND GENERAL METHOD WILL BE DEVELOPED FOR ASSAYING GLYCOSYLTRANSFERASES. THIS NEW TECHNIQUE IS RAPID, 3 TO 6 ORDERS OF MAGNITUDE MORESENSITIVE THAN EXISTING ASSAYS, AND DOES NOT RELY ON THE USEOF RADIOISOTOPES. THIS NEW TECHNOLOGY, DESIGNATED ENZYME LUMINESCENCE ASSAY (ELA), UTILIZES THE REMARKABLE SENSITIVITY OF THE RECOMBINANT, BIOLUMINESCENT PROTEIN, AEQUORIN, AND THE HIGH AFFINITY INTERACTIONS OF STREPTAVIDIN AND BIOTIN. ELA HAS BEEN USED TO DETERMINE THE ACTIVITY OF UDPGAL:BETA-D-GLCNAC(BETA1,4) GALACTOSYLTRANSFERASE. THE SPECIFIC AIMS OF THESE STUDIES ARE: (1) TO DEVELOP ELA'S FOR ADDITIONAL GLYCOSYLTRANSFERASES, INCLUDING UDPGAL:GALBETA1,4GLC(NAC)(ALPHA1,3)GALACTOSYLTRANSFERASE AND CMPNEUAC:GALBETA1,3(4)GLCNAC(ALPHA2,3)SIALYLTRANSFERASE;AND (2) TO ADAPT ELA'S TO A MICROTITER PLATE ASSAY. THE LONG-TERM GOAL IS TO DEVELOP ELA'S FOR A WIDE VARIETY OF GLYCOSYLTRANSFERASES TO ALLOW CLINICAL EVALUATION OF GLYCOSYLTRANSFERASE ACTIVITIES AS DIAGNOSTIC MARKERS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government